X4 PHARMACEUTICALS is a biopharmaceutical company. Co.'s primary clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4, that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, mavorixafor has the potential to provide therapeutic benefit across a variety of neutropenic disorders, including Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, primary immunodeficiency. Co. is also developing mavorixafor in a Phase 2 clinical trial in people with certain neutropenic disorders. We show 18 historical shares outstanding datapoints in our XFOR shares outstanding history coverage, used to compute XFOR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing XFOR market cap history over the course of time is important for investors
interested in comparing XFOR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of XFOR versus a peer is one thing; comparing
XFOR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like XFOR can fluctuate over the course of history.
With this page we aim to empower investors researching XFOR by allowing them to research the XFOR market cap history. |
Free XFOR Email Alerts:
Video: The Importance of Market Cap
